Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys.  "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients.  The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

  • ANA598 Phase IIb Study.  During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  
  • ANA773 Phase IIa Study.  The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with riba
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... 2014 ... has announced the addition of the ... to their offering.      (Logo: ... of chromosomes using molecular biology to understand ... chromosomes. It plays a crucial role in ...
    (Date:9/18/2014)... , Sept. 18, 2014  Low T ... committee meeting in Hyattsville, Maryland ... to assess the proper patient population for testosterone ... cardiovascular risk associated with TRT. Examining recent claims from ... found that "available epidemiological studies do not provide ...
    (Date:9/18/2014)... CITY, Kan. , Sept. 18, 2014 /PRNewswire/ ... a pet therapeutics company focused on licensing, developing ... today announced the full exercise of the underwriters, ... stock in connection with the company,s previously announced ...  All of the shares are being offered by ...
    Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
    (Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
    (Date:9/18/2014)... (PRWEB) September 19, 2014 Reduce bags ... ingredients made just for these issues in a serum. ... Haloxyl and Eyeliss," says Kathy Heshelow, founder of Sublime ... circulation and boosting collagen, to improve the eye area." ... serum for wrinkles, dark circles and bags at ...
    (Date:9/18/2014)... 19, 2014 When Mary Ann Thompson and Mathieu ... who live in Bali, Indonesia with their son, Isaac, said there ... two met at Mercy College in 2001 when Thompson was an ... was a graduate student at the time, was French and so ... and migrated to the United States when she was 7 years ...
    (Date:9/18/2014)... 18, 2014 Defendants in more ... currently pending in Pennsylvania’s Philadelphia Court of Common ... on behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard ... 11th, the defendants maintain that circumstances surrounding the ... lawsuits have no connection to Pennsylvania. The filings ...
    (Date:9/18/2014)... Active Aging Week is a week-long observance ... members of society and promotes the benefits of leading ... a boutique retirement community located at 1200 Overlook Drive, ... of Cyber-Seniors - a humorous and heartwarming documentary. , ... this great film,” says Thomas Cloutier, Executive Director for ...
    Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
    ... Rehab MarketDETROIT, March 10 David Glancy, a complex ... has joined Alliance Seating & Mobility (ASM), ... companies. Glancy is an Assistive Technology Professional ... and provides power mobility solutions for pediatrics and adults ...
    ... WASHINGTON, March 10 To guide healthcare systems in ... the National Quality Forum (NQF) is releasing its 2009 ... pace of adoption of Safe Practices nationwide, a year-long ... Practices implementation strategies and commentary from experts in the ...
    ... soar past $2.5 trillion and more than 47 million people ... medical options to ensure health care reform is successful, argues ... Americans die each year because of their lack of insurance, ... that save very few lives or yield only a few ...
    ... of fondness and relief. Fondness for the good memories, and relief ... gossip, SATs, fights with parents is behind us. ... that even stressful times from the teenage years exact a physical ... , Andrew J. Fuligni, a professor of psychiatry at the ...
    ... ROCHESTER, Minn., March 10 Here are highlights from ... . You may cite this publication as often as ... attribution is required. Reprinting is allowed ... your editorial policies permit: Visit www.bookstore.mayoclinic.com or ...
    ... CPC of America, Inc. (OTC Bulletin Board: ... therapeutic devices that enhance the quality of patient ... is actively pursuing the development of proprietary polyethylene ... global commercialization strategy for MedClose(TM). MedClose(TM) is ...
    Cached Medicine News:Health News:Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 3Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 4Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 2Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 3Health News:Teenage stress has implications for adult health 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 3Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 4Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 5Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 6Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 2Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: